Drug intelligence / Profile preview

HD-BT4801

Development stage: Preclinical
Lead developer: BioArctic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HD-BT4801 is an experimental monoclonal antibody being developed by BioArctic for the treatment of Huntington's disease. The drug targets the huntingtin (HTT) protein, which is central to the pathogenesis of the disease. A key feature of HD-BT4801 is the incorporation of BioArctic's proprietary BrainTransporter™ technology, which is designed to actively transport the antibody across the blood-brain barrier (BBB) into the central nervous system, potentially increasing brain exposure and therapeutic efficacy compared to standard antibodies. The program is currently in the research or preclinical stage.

Other names: HTT monoclonal antibody with BrainTransporter

Targets

HTT (Huntingtin protein)

Beyond the preview

Go deeper on HD-BT4801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD-BT4801.

Explore the full profile